Clinical trials of adjunctive anti-inflammatory drugs, such as NSAIDS, may also be warranted in children with treatment-refractory OCD symptoms. Ultimately, further work is required to better understand the etiologic and prognostic implications of the associations identified in this study, with the goal of improving our understanding of OCD pathogenesis and facilitating the development of adjunctive immune-modulating therapeutic strategies.
